Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial
Study context
- Population
- Patients with nonobstructive coronary artery disease (NOCAD) without prior cardiovascular (CV) events, on maximally tolerated high-intensity statin therapyrandomized, enrolment closed on October 25, 2024
- Participants
- 608 patients
- Planned comparison
- Inclisiran compared to placebo in reducing total coronary atheroma volume
- Primary endpoint
- percentage change from baseline in total coronary atheroma volume, measured by coronary computed tomography angiography (CCTA)
- Follow-up
- Month 24
Methodological details96 sites across 18 countries
- 96 sites across 18 countries
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial. Am Heart J. Published 30 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it